AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients imports. The AHA urged the administration to maintain tariff exceptions, particularly for products already experiencing shortages and for countries that produce a significant portion of the U.S. market supply of pharmaceuticals and pharmaceutical ingredients.

“The lives of patients often depend on the ready availability of drugs to respond to emergent conditions like heart attacks and infections, and other critical illnesses like cancer and organ failure. The supply chain for pharmaceutical products is highly complex and requires hospitals to draw on both domestic and international sources,” the AHA said. “For many patients, even a temporary disruption in their access to these needed medications could put them at significant risk.”

Related News Articles

Chairperson's File
Public
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
President Trump April 9 announced that reciprocal tariffs that went into effect after midnight for certain nations will be paused for 90 days, while tariffs…